How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gentuximab-injection.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Gentuximab Injection — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gentuximab Injection (Gentuximab Injection) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: VEGF inhibitor monoclonal antibody. Area: Oncology.

phase 3 VEGF inhibitor monoclonal antibody VEGF (Vascular Endothelial Growth Factor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gentuximab Injection (Gentuximab Injection) — Changchun GeneScience Pharmaceutical Co., Ltd.. Gentuximab is a monoclonal antibody that targets and inhibits vascular endothelial growth factor (VEGF) to suppress tumor angiogenesis and blood vessel formation.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Gentuximab Injection TARGET	Gentuximab Injection	Changchun GeneScience Pharmaceutical Co., Ltd.	phase 3	VEGF inhibitor monoclonal antibody	VEGF (Vascular Endothelial Growth Factor)
Bevacizumab-awwb	Bevacizumab-awwb	Amgen	marketed	VEGF inhibitor monoclonal antibody / Bevacizumab biosimilar	VEGF (Vascular Endothelial Growth Factor)
QL1101	QL1101	Qilu Pharmaceutical Co., Ltd.	phase 3	VEGF inhibitor monoclonal antibody	VEGF (Vascular Endothelial Growth Factor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (VEGF inhibitor monoclonal antibody class)

Changchun GeneScience Pharmaceutical Co., Ltd. · 1 drug in this class
Qilu Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gentuximab Injection — Competitive Intelligence Brief. https://druglandscape.com/ci/gentuximab-injection. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing